dc.contributor.author |
Verma, Rahul Kumar
|
|
dc.contributor.author |
Germishuizen, Willem Andreas
|
|
dc.contributor.author |
Motheo, M.P. (Mamofalali Portia)
|
|
dc.contributor.author |
Agrawal, Atul Kumar
|
|
dc.contributor.author |
Singh, Amit Kumar
|
|
dc.contributor.author |
Mohan, Mradul
|
|
dc.contributor.author |
Gupta, Pushpa
|
|
dc.contributor.author |
Gupta, Umesh Datta
|
|
dc.contributor.author |
Cholo, Moloko C.
|
|
dc.contributor.author |
Anderson, Ronald
|
|
dc.contributor.author |
Fouche, P. Bernard
|
|
dc.contributor.author |
Misra, Amit
|
|
dc.date.accessioned |
2014-04-10T09:13:00Z |
|
dc.date.available |
2014-04-10T09:13:00Z |
|
dc.date.issued |
2013-02 |
|
dc.description.abstract |
Inhalable clofazimine-containing dry powder microparticles (CFM-DPI) and native clofazimine (CFM) were evaluated for activity against Mycobacterium tuberculosis in human monocyte-derived macrophage cultures and in mice infected with a low-dose aerosol. Both formulations resulted in 99% killing at 2.5 g/ml in vitro. In mice, 480 g and 720 g CFM-DPI inhaled twice per week over 4 weeks reduced numbers of CFU in the lung by as much as log10 2.6; 500 g oral CFM achieved a log10 0.7 reduction. |
en_US |
dc.description.librarian |
am2014 |
en_US |
dc.description.librarian |
ay2014 |
|
dc.description.sponsorship |
The Indian work was funded by a grant from CSIR, India (NWP0035).
R.K.V., A.K.S., and A.K.A. received research fellowships from CSIR, India, and M.M. received one from ICMR, India.
The South African work was supported by The South African Medical Research Council (M.P.M., M.C., R.A.) and a K-RITH collaborative grant (Howard Hughes Medical Institute and the University of KwaZulu-Natal, to P.B.F. and W.A.G.). |
en_US |
dc.description.uri |
http://aac.asm.org/ |
en_US |
dc.identifier.citation |
Verma, RK, Germishuizen, WA, Motheo, MP, Agrawal, AK, Singh, AK, Mohan, M, Gupta, P, Gupta, UD, Cholo, M, Anderson, R, Fourie, PB & Misra, A 2013, 'Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice', Antimicrobial Agents and Chemotherapy , vol. 57, no. 2, pp. 1050-1052. |
en_US |
dc.identifier.issn |
0066-4804 (print) |
|
dc.identifier.issn |
1098-6596 (online) |
|
dc.identifier.other |
10.1128/AAC.01897-12 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/39634 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
American Society for Microbiology |
en_US |
dc.rights |
© 2013, American Society for Microbiology. All Rights Reserved. |
en_US |
dc.subject |
Microparticles |
en_US |
dc.subject |
Clofazimine |
en_US |
dc.subject |
Treatment |
en_US |
dc.subject |
Mice |
en_US |
dc.subject.lcsh |
Tuberculosis -- Treatment -- Research |
en |
dc.title |
Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice |
en_US |
dc.type |
Article |
en_US |